Skip to main content

Table 2 ACT Clinical Trials for PDAC

From: Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma

NCT number Status Intervention Phase Duration Location
NCT03008304 Recruiting High-activity natural killer Phase 1
Phase 2
December 2016–December 2019 Fuda Cancer Institute of Fuda Cancer Hospital, Guangzhou, Guangdong, China
NCT03267173 Recruiting Chimeric antigen receptor T cell Phase 1 June 15, 2017-June 2019 Harbin Medical University, Harbin, Heilongjiang, China
NCT03180437 Recruiting γδ T cell Phase 1
Phase 2
June 15, 2017-June 15, 2020 Biotherapy Centre at Fuda Cancer Hospital, Guangzhou, Guangdong, China
NCT03136406 Active, not recruiting aNK Phase 1
Phase 2
August 14, 2017-December 2018 Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States
NCT03329248 Active, not recruiting haNK Phase 1
Phase 2
November 6, 2017-December 2019 Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States
NCT02929797 Recruiting CD8 + NKG2D+ AKT cells Early Phase 1 August 2016–August 2019 Shanghai General Hospital, Shanghai, China
NCT03323944 Recruiting huCART-meso cells Phase 1 September 15, 2017-September 2021 University of Pennsylvania, Philadelphia, Pennsylvania, United States
NCT02718859 Unknown NK cells Phase 1
Phase 2
March 2016–March 2017 Central Laboratory at Fuda Cancer Hospital, Guangzhou, Guangdong, China
NCT01781520 Completed DC-CIK Phase 1
Phase 2
June 1, 2013-June 13, 2017 Capital Medical University Cancer Center, Beijing, Beijing, China
NCT03387098 Active, not recruiting haNK Phase 1
Phase 2
January 2, 2018-December 2019 Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States
NCT00003780 Unknown Tumour-infiltrating lymphocytes Phase 2 December 1998, the last update posted is December 19,2013 Meyer Pharmaceuticals, LLC, Irvine, California, United States
NCT02529579 Recruiting iAPA-DC/CTL Phase 1
Phase 2
June 2015–December 2019 Changhai Hospital, Second Military Medical University, Shanghai, China
NCT03638193 Recruiting CAR-T-meso cells Not Applicable July 11, 2018-February 1, 2022 Nanjing First Hospital, Nanjing, Jiangsu, China
NCT03013712 Recruiting CAR-T cells targeting EpCAM Phase 1
Phase 2
January 2017–December 2020 IEC of Chengdu Medical College
Chendu, China
NCT01583686 Terminated Anti-mesothelin CAR transduced PBL Phase 1
Phase 2
May 4, 2012-December 17, 2018 National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
NCT01420874 Active, not recruiting EGFR2Bi-coated T cells Phase 1 August 2011–June 2019 Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
NCT03638206 Recruiting Mesothelin targeting CAR-T cells Phase 1
Phase 2
March 1, 2018-March 1, 2023 The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
NCT00909558 Suspended Autologous natural killer/natural killer T cell Phase 1 May 2009, the last update posted is February 24, 2010 Envita Medical Centers, Scottsdale, Arizona, United States
NCT02839954 Unknown Anti-MUC1 CAR-pNK cells Phase 1
Phase 2
July 2016–July 2018 PersonGen BioTherapeutics (Suzhou) Co., Ltd., Suzhou, Jiangsu, China
NCT00019084 Completed Tumour-infiltrating lymphocytes Phase 2 February 1996–May 2003 Medicine Branch, Bethesda, Maryland, United States
NCT03093688 Recruiting iNKT cells and CD8+ T cells Phase 1
Phase 2
March 1, 2017-December 31, 2019 Shanghai Public Health Clinical Center, Shanghai, Shanghai, China
NCT01174121 Recruiting Young tumour-infiltrating lymphocytes Phase 2 August 26, 2018-December 27, 2024 National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
NCT01801852 Unknown NKT cells Not Applicable January 2013–June 2017 Biotherapeutic Department of Chinese PLA General Hospital, Beijing, Beijing, China
NCT02465983 Completed CAR-T-meso-19 T cells Phase 1 May 2015–November 2017 University of California, San Francisco, San Francisco, California, United States
NCT02757391 Not yet recruiting CD8+ T cells Phase 1 December 31, 2018-December 31, 2022 M D Anderson Cancer Center, Houston, Texas, United States
NCT03269526 Active, not recruiting Anti-CD3 x anti-EGFR bispecific antibody (EGFRBi) armed activated T cells (EGFR BATs) Phase 1
Phase 2
July 28, 2017-June 1, 2022 University of Virginia, Charlottesville, Virginia, United States
NCT03682744 Recruiting Anti-CEA CAR-T cells Phase 1 September 13, 2018-September 2019 Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
Roger Williams Medical Center, Providence, Rhode Island, United States
NCT03407040 Enrolling by invitation Generation of cancer antigen-specific T cells from human-induced pluripotent stem cells (iPSCs) Phase: January 30, 2018-December 31, 2030 National Institutes of Health Clinical Center, Bethesda, Maryland, United States
NCT03745326 Recruiting Anti-KRAS G12D mTCR PBL Phase 1
Phase 2
January 16, 2019-December 1, 2028 National Institutes of Health Clinical Center, Bethesda, Maryland, United States
NCT03190941 Recruiting Anti-KRAS G12V mTCR Phase 1
Phase 2
September 21, 2017-June 29, 2028 National Institutes of Health Clinical Center, Bethesda, Maryland, United States
NCT02850536 Active, not recruiting Anti-CEA CAR-T cells Phase 1 February 1, 2017-August 2018 University of Colorado Hospital, Aurora, Colorado, United States
Roger Williams Medical Center, Providence, Rhode Island, United States